File Download
 
 
Supplementary

Conference Paper: SARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection
  • Basic View
  • Metadata View
  • XML View
TitleSARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection
 
AuthorsZheng, B
Du, L
Zhao, G
Lin, Y
Sui, H
Chan, CS
He, Y
Jiang, S
Zhou, Y
Yuen, KY
 
Issue Date2010
 
PublisherPortland Press Ltd.. The Journal's web site is located at http://www.cellbiolint.org/cbi/default.htm
 
CitationThe 8th International Symposium on Frontiers in Life Sciences (生命科學前沿國際研討會 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62 [How to Cite?]
 
AbstractWe have previously reported that a subunit protein vaccine based on receptor binding domain (RBD) of SARS-CoV S protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing antibody (NA) responses in immunized animals. In this study, systemic, mucosal and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the intramuscular (i.m.) and intranasal (i.n.) routes of administration. Our results demonstrated that: (1) the i.n. vaccination induced systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but local humoral immune response was much stronger; (2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-c producing CD3+/CD8+ T cells in both lungs and spleen; (3) the i.n. vaccination induced a similar protection as the i.m. vaccination against SARS-CoV challenge in mice; (4) higher titers of mucosal IgA and serum NA were associated with lower viral load and less pulmonary pathological damage, while no antibody-mediated disease enhancement effect was observed; and (5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.
 
DescriptionTheme: New Advances and Challenges in Multidisciplinary Research
主題: 多學科交叉研究的新進展與挑戰
 
ISSN1065-6995
2013 Impact Factor: 1.635
 
DC FieldValue
dc.contributor.authorZheng, B
 
dc.contributor.authorDu, L
 
dc.contributor.authorZhao, G
 
dc.contributor.authorLin, Y
 
dc.contributor.authorSui, H
 
dc.contributor.authorChan, CS
 
dc.contributor.authorHe, Y
 
dc.contributor.authorJiang, S
 
dc.contributor.authorZhou, Y
 
dc.contributor.authorYuen, KY
 
dc.date.accessioned2011-07-27T02:00:05Z
 
dc.date.available2011-07-27T02:00:05Z
 
dc.date.issued2010
 
dc.description.abstractWe have previously reported that a subunit protein vaccine based on receptor binding domain (RBD) of SARS-CoV S protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing antibody (NA) responses in immunized animals. In this study, systemic, mucosal and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the intramuscular (i.m.) and intranasal (i.n.) routes of administration. Our results demonstrated that: (1) the i.n. vaccination induced systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but local humoral immune response was much stronger; (2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-c producing CD3+/CD8+ T cells in both lungs and spleen; (3) the i.n. vaccination induced a similar protection as the i.m. vaccination against SARS-CoV challenge in mice; (4) higher titers of mucosal IgA and serum NA were associated with lower viral load and less pulmonary pathological damage, while no antibody-mediated disease enhancement effect was observed; and (5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionTheme: New Advances and Challenges in Multidisciplinary Research
 
dc.description主題: 多學科交叉研究的新進展與挑戰
 
dc.description.otherThe 8th International Symposium on Frontiers in Life Sciences (生命科學前沿國際研討會 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62
 
dc.identifier.citationThe 8th International Symposium on Frontiers in Life Sciences (生命科學前沿國際研討會 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62 [How to Cite?]
 
dc.identifier.epageS62
 
dc.identifier.hkuros188731
 
dc.identifier.issn1065-6995
2013 Impact Factor: 1.635
 
dc.identifier.issue8
 
dc.identifier.spageS62
 
dc.identifier.urihttp://hdl.handle.net/10722/135932
 
dc.identifier.volume34
 
dc.languageeng
 
dc.publisherPortland Press Ltd.. The Journal's web site is located at http://www.cellbiolint.org/cbi/default.htm
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofCell Biology International
 
dc.rightsThe final version of record is available at [Journal URL].
 
dc.titleSARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zheng, B</contributor.author>
<contributor.author>Du, L</contributor.author>
<contributor.author>Zhao, G</contributor.author>
<contributor.author>Lin, Y</contributor.author>
<contributor.author>Sui, H</contributor.author>
<contributor.author>Chan, CS</contributor.author>
<contributor.author>He, Y</contributor.author>
<contributor.author>Jiang, S</contributor.author>
<contributor.author>Zhou, Y</contributor.author>
<contributor.author>Yuen, KY</contributor.author>
<date.accessioned>2011-07-27T02:00:05Z</date.accessioned>
<date.available>2011-07-27T02:00:05Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>The 8th International Symposium on Frontiers in Life Sciences (&#29983;&#21629;&#31185;&#23416;&#21069;&#27839;&#22283;&#38555;&#30740;&#35342;&#26371; 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62</identifier.citation>
<identifier.issn>1065-6995</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135932</identifier.uri>
<description>Theme: New Advances and Challenges in Multidisciplinary Research</description>
<description>&#20027;&#38988;: &#22810;&#23416;&#31185;&#20132;&#21449;&#30740;&#31350;&#30340;&#26032;&#36914;&#23637;&#33287;&#25361;&#25136;</description>
<description.abstract>We have previously reported that a subunit protein vaccine based on receptor binding domain (RBD) of SARS-CoV S protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing antibody (NA) responses in immunized animals. In this study, systemic, mucosal and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the intramuscular (i.m.) and intranasal (i.n.) routes of administration. Our results demonstrated that: (1) the i.n. vaccination induced systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but local humoral immune response was much stronger; (2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-c producing CD3+/CD8+ T cells in both lungs and spleen; (3) the i.n. vaccination induced a similar protection as the i.m. vaccination against SARS-CoV challenge in mice; (4) higher titers of mucosal IgA and serum NA were associated with lower viral load and less pulmonary pathological damage, while no antibody-mediated disease enhancement effect was observed; and (5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.</description.abstract>
<language>eng</language>
<publisher>Portland Press Ltd.. The Journal&apos;s web site is located at http://www.cellbiolint.org/cbi/default.htm</publisher>
<relation.ispartof>Cell Biology International</relation.ispartof>
<rights>The final version of record is available at [Journal URL].</rights>
<title>SARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection</title>
<type>Conference_Paper</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.hkuros>188731</identifier.hkuros>
<identifier.volume>34</identifier.volume>
<identifier.issue>8</identifier.issue>
<identifier.spage>S62</identifier.spage>
<identifier.epage>S62</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
<description.other>The 8th International Symposium on Frontiers in Life Sciences (&#29983;&#21629;&#31185;&#23416;&#21069;&#27839;&#22283;&#38555;&#30740;&#35342;&#26371; 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/135932/1/re01.htm</bitstream.url>
</item>